143 related articles for article (PubMed ID: 36055752)
1. PP2A regulates metastasis and vasculogenic mimicry formation via PI3K/AKT/ZEB1 axis in non-small cell lung cancers.
Zhang Y; Wang X; Li A; Guan Y; Shen P; Ni Y; Han X
J Pharmacol Sci; 2022 Oct; 150(2):56-66. PubMed ID: 36055752
[TBL] [Abstract][Full Text] [Related]
2. Tumor-expressed B7-H3 promotes vasculogenic mimicry formation rather than angiogenesis in non-small cell lung cancer.
Fan X; Huang J; Hu B; Zhou J; Chen L
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8729-8741. PubMed ID: 37129607
[TBL] [Abstract][Full Text] [Related]
3. BENC-511, a novel PI3K inhibitor, suppresses metastasis of non-small cell lung cancer cells by modulating β-catenin/ZEB1 regulatory loop.
Zhang Q; Zhou L; Guan Y; Cheng Y; Han X
Chem Biol Interact; 2018 Oct; 294():18-27. PubMed ID: 30125547
[TBL] [Abstract][Full Text] [Related]
4. RHBDD1 silencing inhibited cell growth and invasion of non-small cell lung cancer by mediating ZEB1/PI3K/AKT signaling pathway.
Xu Z; Wang R; Li X; Yang L; Peng H; Wang Y; Wang P
J Mol Histol; 2021 Jun; 52(3):503-510. PubMed ID: 33515112
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 knockdown suppresses vasculogenic mimicry of non-small cell lung cancer by modulating ZEB1-triggered EMT.
Li W; Wu J; Jia Q; Shi Y; Li F; Zhang L; Shi F; Wang X; Wu S
BMC Cancer; 2024 May; 24(1):633. PubMed ID: 38783271
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of PD-L1 expression in non-small cell lung cancer may reduce vasculogenic mimicry formation by inhibiting the epithelial mesenchymal transformation process.
Shi Y; Li W; Jia Q; Wu J; Wu S; Wu S
Exp Cell Res; 2024 Apr; 437(1):113996. PubMed ID: 38508327
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of ZEB1 suppressed the formation of vasculogenic mimicry and epithelial-mesenchymal transition in the human breast cancer cell line MDA-MB-231.
Liang W; Song S; Xu Y; Li H; Liu H
Mol Med Rep; 2018 May; 17(5):6711-6716. PubMed ID: 29512767
[TBL] [Abstract][Full Text] [Related]
8. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1.
Zhou G; Zhang F; Guo Y; Huang J; Xie Y; Yue S; Chen M; Jiang H; Li M
Biomed Pharmacother; 2017 Jan; 85():113-119. PubMed ID: 27930974
[TBL] [Abstract][Full Text] [Related]
9. Salvianolic acid A blocks vasculogenic mimicry formation in human non-small cell lung cancer via PI3K/Akt/mTOR signalling.
Jin L; Chen C; Huang L; Bu L; Zhang L; Yang Q
Clin Exp Pharmacol Physiol; 2021 Apr; 48(4):508-514. PubMed ID: 33529404
[TBL] [Abstract][Full Text] [Related]
10. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
[TBL] [Abstract][Full Text] [Related]
11. LncRNA-SERB promotes vasculogenic mimicry (VM) formation and tumor metastasis in renal cell carcinoma.
Tang S; Chen F; Zhang J; Chang F; Lv Z; Li K; Li S; Hu Y; Yeh S
J Biol Chem; 2024 May; 300(5):107297. PubMed ID: 38641065
[TBL] [Abstract][Full Text] [Related]
12. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
Zhou Y; Li S; Li J; Wang D; Li Q
Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
[TBL] [Abstract][Full Text] [Related]
14. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
Zheng R; Jiang H; Li J; Liu X; Xu H
Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
[TBL] [Abstract][Full Text] [Related]
15. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
[TBL] [Abstract][Full Text] [Related]
16. The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.
Wang J; Ma S; Chen X; Zhang S; Wang Z; Mei Q
Invest New Drugs; 2019 Oct; 37(5):828-836. PubMed ID: 30456603
[TBL] [Abstract][Full Text] [Related]
17. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
[TBL] [Abstract][Full Text] [Related]
18. The role of sema4D in vasculogenic mimicry formation in non-small cell lung cancer and the underlying mechanisms.
Xia Y; Cai XY; Fan JQ; Zhang LL; Ren JH; Li ZY; Zhang RG; Zhu F; Wu G
Int J Cancer; 2019 May; 144(9):2227-2238. PubMed ID: 30374974
[TBL] [Abstract][Full Text] [Related]
19. Luteolin inhibits viability, migration, angiogenesis and invasion of non-small cell lung cancer vascular endothelial cells via miR-133a-3p/purine rich element binding protein B-mediated MAPK and PI3K/Akt signaling pathways.
Pan J; Cai X; Zheng X; Zhu X; Feng J; Wang X
Tissue Cell; 2022 Apr; 75():101740. PubMed ID: 35101688
[TBL] [Abstract][Full Text] [Related]
20. Doxazosin inhibits vasculogenic mimicry in human non‑small cell lung cancer through inhibition of the VEGF‑A/VE‑cadherin/mTOR/MMP pathway.
Hsu JL; Leu WJ; Hsu LC; Hsieh CH; Guh JH
Oncol Lett; 2024 Apr; 27(4):170. PubMed ID: 38455663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
